The diminished secretion and/or action of insulin, which is associated with the formation of advanced glycation end-products (AGEs) induced by oxidative stress and hyperglycemia, debilitates new bone formation by decreasing osteoblast activity and increasing osteoclast activity, thus reducing bone mass 21,22. The gene discussed is INS; the disease is Hyperglycemia.